Literature DB >> 22668828

Glioblastoma cancer stem cells--from concept to clinical application.

Barbara E Stopschinski1, Christoph P Beier, Dagmar Beier.   

Abstract

Ten years after the first description of cancer stem cells (CSCs) in glioblastoma (GBM), the initial concept of CSC has been challenged and our understanding of cellular heterogeneity within malignant brain tumors became more complex. The increasing knowledge on CSC also influences preclinical research and clinical practice. This review therefore describes current concepts and controversies on CSC in GBM and summarizes the recent progress how the CSC hypothesis is about to translate into preclinical and clinical application.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CD133; Cancer stem cells; Chemoresistance; Glioblastoma; Radioresistance

Mesh:

Substances:

Year:  2012        PMID: 22668828     DOI: 10.1016/j.canlet.2012.05.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

1.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

2.  KCTD2, an adaptor of Cullin3 E3 ubiquitin ligase, suppresses gliomagenesis by destabilizing c-Myc.

Authors:  Eun-Jung Kim; Sung-Hak Kim; Xiong Jin; Xun Jin; Hyunggee Kim
Journal:  Cell Death Differ       Date:  2017-01-06       Impact factor: 15.828

3.  MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133+ Glioblastoma Stem Cells.

Authors:  Liang Yang; Nan Li; Zhongjie Yan; Chen Li; Zongmao Zhao
Journal:  J Mol Neurosci       Date:  2018-09-29       Impact factor: 3.444

4.  Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.

Authors:  Tadas K Rimkus; Richard L Carpenter; Sherona Sirkisoon; Dongqin Zhu; Boris C Pasche; Michael D Chan; Glenn J Lesser; Stephen B Tatter; Kounosuke Watabe; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Res       Date:  2018-02-20       Impact factor: 12.701

Review 5.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

6.  Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact.

Authors:  O Fornara; J Bartek; A Rahbar; J Odeberg; Z Khan; I Peredo; P Hamerlik; J Bartek; G Stragliotto; N Landázuri; C Söderberg-Nauclér
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

7.  Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide.

Authors:  Javier Megías; Alba Martínez; Teresa San-Miguel; Rosario Gil-Benso; Lisandra Muñoz-Hidalgo; David Albert-Bellver; Amara Carratalá; Daniel Gozalbo; Concha López-Ginés; María Luisa Gil; Miguel Cerdá-Nicolás
Journal:  Invest New Drugs       Date:  2019-05-11       Impact factor: 3.850

8.  Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.

Authors:  Jianfang Ning; Hiroaki Wakimoto; Cole Peters; Robert L Martuza; Samuel D Rabkin
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

9.  High expression of miR-9 in CD133+ glioblastoma cells in chemoresistance to temozolomide.

Authors:  Jessian L Munoz; Vivian Rodriguez-Cruz; Pranela Rameshwar
Journal:  J Cancer Stem Cell Res       Date:  2015-02-27

Review 10.  What is the most appropriate clinical target volume for glioblastoma?

Authors:  Simon S Lo; Arjun Sahgal; Ben J Slotman; David B Mansur; Anton Khouri; Andrew E Sloan; Mitchell Machtay; Eric L Chang
Journal:  CNS Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.